CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal cancer.
  
  LEARNING OBJECTIVES

  • Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering clinical and biologic factors such as age, performance status and disease stage.
  • Develop a long-term plan to guide the selection and sequencing of therapy for patients diagnosed with metastatic CRC (mCRC), considering biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals for treatment.
  • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into care.
  • Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future role of various investigational approaches.
  • Evaluate available data with and FDA approvals of immune checkpoint inhibitor therapies for microsatellite instability-high or mismatch repair-deficient mCRC, and optimally select patients for these approaches.
  • Apply available and emerging research to optimize the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC.
  • Recall ongoing trials evaluating novel agents and strategies for CRC, and use this information to refer appropriate patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Kristen K Ciombor, MD, MSCI
  Associate Professor of Medicine
  Division of Hematology/Oncology
  Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee
  
  Advisory Committee: Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Consulting Agreements: Merck, Seagen Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc.
  
  Cathy Eng, MD
  Professor of Medicine
  Co-Leader, VICC Gastrointestinal Cancer Research Program
  David H Johnson Chair in Surgical and Medical Oncology
  Co-Director, GI Oncology
  Director, VICC Young Adults Program
  Co-Chair, NCI Gastrointestinal Steering Committee
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Gilead Sciences Inc, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Natera Inc; Contracted Research: Elevar Therapeutics, Hutchison MediPharma; Data and Safety Monitoring Board/Committee: Mirati Therapeutics, Veloxis Pharmaceuticals.
  
  Pashtoon M Kasi, MD, MS
  Director, Colon Cancer Research
  Director, Liquid Biopsy Research
  Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
  Englander Institute for Precision Medicine
  Division of Hematology and Medical Oncology
  NewYork-Presbyterian Hospital/Weill Cornell Medicine
  New York, New York
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Axiom Healthcare Strategies, Bayer HealthCare Pharmaceuticals, Boston Healthcare Associates Inc, Delcath Systems Inc, Exact Sciences Inc, Foundation Medicine, Inflection Point Biomedical Advisors, Ipsen Biopharmaceuticals Inc (institution), Lilly, Merck Sharp & Dohme Corp, Natera Inc, QED Therapeutics, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Taiho Pharmaceutical Group, Tempus; Contracted Research: Advanced Accelerator Applications, Array BioPharma Inc, a subsidiary of Pfizer Inc, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, TerSera Therapeutics LLC; Travel, Accommodations, Expenses: AstraZeneca Pharmaceuticals LP.
  
  Christopher Lieu, MD
  Associate Professor of Medicine
  Associate Director for Clinical Research
  Co-Director, GI Medical Oncology
  University of Colorado Cancer Center
  Aurora, Colorado
  
  No relevant conflicts of interest to disclose.
  
  Alan P Venook, MD
  The Madden Family Distinguished Professor of Medical Oncology and Translational Research
  Shorenstein Associate Director, Program Development
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Exelixis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Pierre Fabre, QED Therapeutics, a BridgeBio company.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Natera Inc and Taiho Oncology Inc.
  
  Release date: February 2022
  Expiration date: February 2023